Armodafinil is a slightly stronger derivative of Modafinil that promotes wakefulness and alertness with effects that are thought to last longer. Considered a “smart drug” it is sometimes used as an off-label as a cognitive enhancer to promote a boost in mental performance, focus and the ability to stay productive.
What is Armodafinil (Nuvigil)?
Armodafinil is a wakefulness-promoting Nootropic smart drug that is sold as a prescription medication under the brand names Nuvigil and Waklert.
This drug was approved by the Food and Drug Administration (FDA) in 2007 as a schedule IV prescription drug used to treat chronic daytime fatigue for people suffering from shift work disorder, narcolepsy and other sleeping disorders.
Armodafinil is also commonly used off-label, even by healthy individuals, observed to promote a long-lasting, natural sense of physical and mental energy and alertness that leads to overall enhanced mental performance.
By promoting wakefulness, users of this drug say they experience an increased ability to focus on tasks at hand, the ability to concentrate is improved and they can function at a more productive, enjoyable level.
Armodafinil is part of a class of eugeroic drugs originally developed in the 1970’s which additionally include Modafinil and their legal alternative, which does not require a prescription, Adrafinil. Eugeroics, from the Greek word “good arousal”, are a class of stimulants that promote wakefulness and alert mental states but are considered to lack the adverse side effects that are typical to stimulants.
Nuvigil (Armodafinil) is a derivative of Provigil (Modafinil). These two drugs are manufactured by the same company, Cephalon Inc. now Teva Pharmaceuticals and are both prescriptive medications with many similar effects.
Although there is no information on exactly how Nuvigil is made, it’s chemical makeup is known to be a purified single-enantiomer version of Provigil. This modified chemical structure made the effects slightly stronger, last longer and may provide additional benefits.
Armodafinil (Nuvigil) Primary Uses
Armodafinil (brand names Nuvigil or Waklert) was developed as a wakefulness enhancer, intended to be used for excessive daytime fatigue in individuals suffering from narcolepsy, obstructive sleep apnea, idiopathic hypersomnia and shift work disorder.
It was also considered as a treatment for jet lag (which many experts still believe it is effective for), symptoms of schizophrenia and depression, however, it is not an approved pharmaceutical for any these applications.
The main effect of Armodafinil is eugeroic, promoting wakefulness and alertness by targeting brain chemical systems that regulate mental arousal (when stimulation is required) rather than targeting the entire nervous system like traditional stimulants.
This system is believed to allow a user to have a powerful smooth boost of energy throughout the day without typically affecting normal sleeping patterns.
In addition, eugeroics do not raise blood pressure or increase heart rate. Nuvigil is unlikely to cause symptoms of chemical withdrawal (“comedown symptoms”).
Nuvigil has been progressively suggested to treat and manage symptoms of Attention Deficit Hyperactivity Disorder (ADHD) and ADD in adults. This drug is said to have stimulant-like effects but does not carry many of the potential adverse side effects associated with stimulating drugs that are used to treat these conditions like Adderall or Ritalin.
In addition, Armodafinil is a derivative of another popular eugeroic drug Modafinil (Provigil) which is more commonly used off-label for ADHD.
Although there is growing popularity for the use of Nugivil and Provigil for ADHD, this is considered an off-label use of this drug. Both these drugs are only approved by the FDA for sleeping disorders.
In addition, it is difficult to obtain a prescription to use these drugs for this condition since they are still in the experimental phase. Insurance companies do not cover any off-label uses of Nuvigil or Provigil.
Armodafinil Uses for Depression and Anxiety Relief
Nuvigil (Armodafinil) drug effects were designed primarily to aid in wakefulness and alertness but it may be a great short-term potential defense against inconsistent and changeable thoughts that accompany anxiety, depression and mood imbalances.
It has been noted to be used for many off-label benefits including greatly enhancing the ability to focus and concentrate without distraction in addition to boosting mental energy.
These effects may help control depressive or anxious thoughts, basically allowing for the ability to focus outward which may reduce the tendencies towards panic attacks and social anxiety.
This drug also seems to have significant mood-boosting effects. It has been observed by many people to promote a happier mood, decrease feelings of stress, increase the level of confidence and boost motivation.
Although the exact mechanisms of action of Armodafinil (Nuvigil) are not fully understood, it appears to work by inhibiting the reuptake of Dopamine, leading to increases in extracellular levels in certain areas of the brain.
Although the effects of Nuvigil are promising for those suffering from depression and anxiety, it is a prescriptive medication for people diagnosed with a sleeping disorder and you cannot get a prescription to use this drug for these off-label purposes.
Armodafinil Benefits for Cognition
Armodafinil is also sometimes used off-label, in non-clinical settings to help boost brain power and promote cognitive enhancement. Anecdotal reports suggest benefits including enhanced focus, reduced brain fog, significant improvements in concentration and alleviation of fatigue.
Although this is a prescriptive drug approved by the FDA to treat sleeping disorders, many users have also reported that Armodafinil offers additional powerful effects on motivation and even mood with limited side effects.
Users describe the effects as a flow-like energetic and motivational state with the ability to have sharper mental connections that lead to a highly productive state. It is also reported to boost alertness beyond the effects of caffeine, which is a traditional stimulant
Buying Armodafinil (Nuvigil) Online
Nuvigil requires a prescription from a doctor in order to buy it legally both off and online. It is a Schedule 4 controlled substance in the United States, a schedule reserved for drugs that have a lower potential for abuse but can be harmful if taken in large quantities or abused.
There are many offshore pharmacies from countries such as Mexico or India that sell Armodafinil or Nuvigil generics online without requiring a prescription. This method is strongly not recommended.
Illegally sold medications are often seized at customs and can pose potential criminal charges if you can’t produce a prescription for this drug and in most cases, with no refund. This also applies to those living in Canada, Europe and the UK.
In addition, if you do have a prescription for Nuvigil you must keep in mind that there may be inferior quality control standards in these countries. That can pose a potential risk that the product can be contaminated or not contain Nuvigil at all.
Finally, the manufacturer of Nugivil, Cephalon Inc., does not recommend this drug to be used by anyone under the age of 18 since there have been no significant studies done to determine the safety of Nuvigil use for children.
Alternatives for Nuvigil To Consider
If you are interested in experiencing the effects of Nuvigil there are other legal alternatives that you may want to consider.
There are many Nootropic supplements to explore since they act to work with your brains chemistry to produce many substantial improvements in both cognitive functions and aspects of mood.
However, if you are looking for the closest compound related to Nuvigil, Adrafinil is the most popular alternative. This is another eugeroic substance considered to have identical effects and is not known to have the potential risk of dependency. It does not require a prescription and is legal to buy in the United States and most other countries.
Adrafinil converts in the body to Modafinil and Nuvigil is a modified version of this drug. Adrafinil may not be suitable for everyone, to learn more about these drugs and if they may be right for you, it is best to speak with your doctor first.
In addition, there are many Nootropics that are known to promote positive effects on mood and are considered by many people as a notable way to help fight against symptoms of depression and anxiety that may be worth looking into
Rate this article :
TOP 10 BEST SELLING NOOTROPIC SUPPLEMENTS
30 day money back guarantee
Free Domestic shipping.
Tested for quality and purity
- Drake C, Gumenyuk V, Roth T, Howard R. Effects of armodafinil on simulated driving and alertness in shift work disorder. Sleep. 2014 Dec 1;37(12):1987-94. doi: 10.5665/sleep.4256.[source]
- Vetrivelan R, Saper CB, Fuller PM. Armodafinil-induced wakefulness in animals with ventrolateral preoptic lesions. Nat Sci Sleep. 2014 May 2;6:57-63. doi: 10.2147/NSS.S53132. eCollection 2014.[source]
- Roscoe JA, Garland SN, Heckler CE, Perlis ML, Peoples AR, Shayne M, Savard J, Daniels NP, Morrow GR. Randomized placebo-controlled trial of cognitive behavioral therapy and armodafinil for insomnia after cancer treatment. J Clin Oncol. 2015 Jan 10;33(2):165-71. doi: 10.1200/JCO.2014.57.6769. Epub 2014 Dec 1. PubMed PMID: 25452447;[source]
- Darwish M, Kirby M, Hellriegel ET, Robertson P Jr. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug Investig. 2009;29(9):613-23. doi: 10.[source]
- Roth T, Freeman J, Zammit G, Donnelly P, Gao J, Ferreira-Cornwell MC, Gasior M. A generalized estimating equation approach to analysis of maintenance of wakefulness testing in a study of lisdexamfetamine dimesylate, armodafinil, and placebo in sleep-deprived adults. J Clin Psychopharmacol. 2014 Oct;34(5):642-4.[source]
- Darwish M, Kirby M, D’Andrea DM, Yang R, Hellriegel ET, Robertson P Jr. Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study. Clin Ther. 2010 Nov;32(12):2074-87. doi: 10.1016/j.clinthera.2010.11.009.[source]
- Darwish M, Bond M, Yang R, Hellriegel ET, Robertson P Jr. Evaluation of the potential for pharmacokinetic drug-drug interaction between armodafinil and carbamazepine in healthy adults. Clin Ther. 2015 Feb 1;37(2):325-37. doi: 10.1016/j.clinthera.2014.09.014.[source]
- Fiocchi EM, Lin YG, Aimone L, Gruner JA, Flood DG. Armodafinil promotes wakefulness and activates Fos in rat brain. Pharmacol Biochem Behav. 2009 May;92(3):549-57. doi: 10.1016/j.pbb.2009.02.006. Epub 2009 Feb 26.[source]
- Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013 Nov;74(11):1101-7. doi: 10.4088/JCP.13r08560. Review.[source]
- Czeisler CA, Walsh JK, Wesnes KA, Arora S, Roth T. Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Mayo Clin Proc. 2009 Nov;84(11):958-72. doi: 10.1016/S0025-6196(11)60666-6.[source]
- Harsh JR, Hayduk R, Rosenberg R, Wesnes KA, Walsh JK, Arora S, Niebler GE, Roth T. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006 Apr;22(4):761-74.[source]
- Howard R, Roth T, Drake CL. The effects of armodafinil on objective sleepiness and performance in a shift work disorder sample unselected for objective sleepiness. J Clin Psychopharmacol. 2014 Jun;34(3):369-73. doi: 10.1097/JCP[source]
- Wisor JP, Dement WC, Aimone L, Williams M, Bozyczko-Coyne D. Armodafinil, the R-enantiomer of modafinil: wake-promoting effects and pharmacokinetic profile in the rat. Pharmacol Biochem Behav. 2006 Nov;85(3):492-9. Epub 2006 Nov 28.[source]
- Kane JM, Yang R, Youakim JM. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study. Schizophr Res. 2012 Mar;135(1-3):116-22. doi: 10.1016/j.schres.2011.11.006. Epub 2011 Dec 16[source]
- Loland CJ, Mereu M, Okunola OM, Cao J, Prisinzano TE, Mazier S, Kopajtic T, Shi L, Katz JL, Tanda G, Newman AH. R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry. 2012 Sep 1;72(5):405-13. doi: 10.1016/j.biopsych.2012.03.022. Epub 2012 Apr 25.[source]
- Spencer TJ, Madras BK, Bonab AA, Dougherty DD, Clarke A, Mirto T, Martin J, Fischman AJ. A positron emission tomography study examining the dopaminergic activity of armodafinil in adults using [¹¹C]altropane and [¹¹C]raclopride. Biol Psychiatry. 2010 Nov 15;68(10):964-70. doi: 10.1016/j.biopsych.2010.08.026.[source]
- McCarty DE. Ready for takeoff? A critical review of armodafinil and modafinil for the treatment of sleepiness associated with jet lag. Nat Sci Sleep. 2010 May 17;2:85-94. Print 2010. PubMed PMID: 23616701;[source]
- Conrado DJ, Bewernitz M, Ding M, Cibula J, Seubert C, Sy SK, Eisenschenk S, Derendorf H. Electroencephalogram effects of armodafinil: comparison with behavioral alertness. J Clin Pharmacol. 2013 Oct;53(10):1058-71. doi: 10.1002/jcph.143. Epub 2013 Aug 1.[source]
- Darwish M, Bond M, Yang R, Hellriegel ET, Robertson P Jr. Evaluation of the potential for pharmacokinetic drug-drug interaction between armodafinil and carbamazepine in healthy adults. Clin Ther. 2015 Feb 1;37(2):325-37. doi: 10.1016/j.clinthera.2014.09.014. Epub 2014 Oct 16.[source]
- National Center for Biotechnology Information. PubChem Compound Database; CID=9690109, https://pubchem.ncbi.nlm.nih.gov/compound/9690109 (accessed Apr. 15, 2018).[source]
- Andrade C, Kisely S, Monteiro I, Rao S. Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res. 2015 Jan;60:14-21. doi: 10.1016/j.jpsychires.2014.09.013[source]